Zhongda Hospital, Medical School, Southeast University
Welcome,         Profile    Billing    Logout  
 12 Trials 
11 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Ling
AK0529-2007, NCT06775405: A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants

Recruiting
3
180
RoW
AK0529, Placebo
Shanghai Ark Biopharmaceutical Co., Ltd.
Respiratory Synctial Virus Infections
08/25
09/25
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
928
Europe, Canada, Japan, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec
Eli Lilly and Company
Diabetes, Type 2 Diabetes
04/24
04/24
SURPASS-CN-INS, NCT05691712: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Completed
3
257
RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
07/24
07/24
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Recruiting
2
185
RoW
HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor
Hutchison Medipharma Limited
Marginal Zone Lymphoma, Follicular Lymphoma
04/24
12/24
TRS00501001, NCT05395533: A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

Recruiting
1
152
RoW
Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005
Zhejiang Teruisi Pharmaceutical Inc.
CD20-positive B-cell Non-Hodgkin Lymphoma
12/23
12/24
OPTIMAL, NCT03084991: OPTical Coherence Tomography IMAging in Patients With Acute myocardiaL Infarction

Recruiting
N/A
4500
RoW
Harbin Medical University, Abbott
Acute Myocardial Infarction
07/21
12/22
NCT05227677: Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes

Active, not recruiting
N/A
200
RoW
GA guided anti-diabetic therapy adjustment, current guidelines to adjust treatment
Asahi Kasei Pharma Corporation
Type 2 Diabetes Mellitus
08/24
12/24
NCT05597709: Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China

Recruiting
N/A
2900
RoW
Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination
Wuxi Hisky Medical Technology Co Ltd, Zhongda Hospital, Medical School, Southeast University, Suzhou Municipal Hospital, Suzhou Fifth People's Hospital, Xuzhou Mining Group General Hospital, Nantong First People's Hospital, Changzhou Second People's Hospital, Huaian Second People's Hospital, Huaian Hospital, Taizhou Jiangyan Traditional Chinese Medicine Hospital, Yangzhou Jiangdu People's Hospital, Huaian Xuyi County People's Hospital
Type 2 Diabetes Mellitus in Remission, Metabolic Associated Fatty Liver Disease
06/23
06/27
Shi, Ruihua
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Ju, Shenghong
No trials found

Download Options